Education
About Us
Working with TipRanks
Follow Us
Alaunos Therapeutics (TCRT)
NASDAQ:TCRT
RESEARCH TOOLSreports
Total Valuation
Alaunos Therapeutics has a market cap or net worth of $4.75M. The enterprise value is $3.47M.
Market Cap$4.75M
Enterprise Value$3.47M
Share Statistics
Alaunos Therapeutics has 1,639,521 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,639,521
Owned by Insiders17.95%
Owned by Institutions<0.01%
Financial Efficiency
Alaunos Therapeutics’s return on equity (ROE) is -5.57 and return on invested capital (ROIC) is -543.32%.
Return on Equity (ROE)-5.57
Return on Assets (ROA)-4.25
Return on Invested Capital (ROIC)-543.32%
Return on Capital Employed (ROCE)-5.43
Revenue Per Employee5.00K
Profits Per Employee-35.14M
Employee Count1
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Alaunos Therapeutics is -0.48. Alaunos Therapeutics’s PEG ratio is 0.03.
PE Ratio-0.48
PS Ratio0.00
PB Ratio2.69
Price to Fair Value2.69
Price to FCF-0.56
Price to Operating Cash Flow-0.56
PEG Ratio0.03
Income Statement
In the last 12 months, Alaunos Therapeutics had revenue of 5.00K and earned -35.14M in profits. Earnings per share was -21.97.
Revenue5.00K
Gross Profit-4.80M
Operating Income-34.27M
Pretax Income-35.14M
Net Income-35.14M
EBITDA-30.90M
Earnings Per Share (EPS)-21.97
Cash Flow
In the last 12 months, operating cash flow was 15.67M and capital expenditures 2.25M, giving a free cash flow of 17.91M billion.
Operating Cash Flow15.67M
Free Cash Flow17.91M
Free Cash Flow per Share10.93
Dividends & Yields
Alaunos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.91
52-Week Price Change-77.37%
50-Day Moving Average2.15
200-Day Moving Average2.27
Relative Strength Index (RSI)60.21
Average Volume (3m)998.13K
Important Dates
Alaunos Therapeutics upcoming earnings date is Nov 7, 2024, TBA Not Confirmed.
Last Earnings DateAug 8, 2024
Next Earnings DateNov 7, 2024
Ex-Dividend Date―
Financial Position
Alaunos Therapeutics as a current ratio of 4.22, with Debt / Equity ratio of 0.00%
Current Ratio4.22
Quick Ratio4.22
Debt to Market Cap0.00
Net Debt to EBITDA0.20
Interest Coverage Ratio-17.84
Taxes
In the past 12 months, Alaunos Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Alaunos Therapeutics EV to EBITDA ratio is -0.35, with an EV/FCF ratio of -0.36.
EV to Sales2.18K
EV to EBITDA-0.35
EV to Free Cash Flow-0.36
EV to Operating Cash Flow-0.36
Balance Sheet
Alaunos Therapeutics has $1.68M in cash and marketable securities with ― in debt, giving a net cash position of -$1.68M billion.
Cash & Marketable Securities$1.68M
Total Debt―
Net Cash-$1.68M
Net Cash Per Share-$1.03
Tangible Book Value Per Share$3.94
Margins
Gross margin is -3966.67%, with operating margin of -685340.00%, and net profit margin of -702800.00%.
Gross Margin-3966.67%
Operating Margin-685340.00%
Pretax Margin-702800.00%
Net Profit Margin-702800.00%
EBITDA Margin-618080.00%
EBIT Margin-664380.00%
Analyst Forecast
The average price target for Alaunos Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast80.00%
EPS Growth Forecast86.70%